ArticleScience advances2016
Material-driven fibronectin assembly for high-efficiency presentation of growth factors.
Article in Science advances, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 138 citations in OpenAlex.
- Modulating Integrin and Growth Factor Signaling With Peptides: Strategies to Synergistically Enhance Bone Tissue Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Leveraging Viscosity to Unlock the Osteogenic Potential of BMP-2 Mimetic DWIVA.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Specific and non-specific interactions of fibronectin with zwitterionic peptoid brushes studied by molecular dynamics simulation.Physical chemistry chemical physics : PCCP · 2025Article
- Enhancing the Potency of Growth Factor-Mimicking Peptides via Cross-Presentation With Integrin Ligands.Journal of biomedical materials research. Part A · 2025Article
- Osteogenesis enhancement by immobilized DOPA-BMP-2 in combination with ultrasonic stimulation.RSC advances · 2025Article
- The pivotal role of cytokines in liver disease pathogenesis and therapeutic potential.Frontiers in immunology · 2025Review
- An In Vitro Model of the Blood-Brain Barrier for the Investigation and Isolation of the Key Drivers of Barriergenesis.Advanced healthcare materials · 2024Article
- Tissue-engineered fibrillar fibronectin matrices are not only lovely, but also functional for regenerative medicines andBiomaterials and biosystems · 2024Article
- Considerations of growth factor and material use in bone tissue engineering using biodegradable scaffolds in vitro and in vivo.Scientific reports · 2024Article
- Nanotopography Influences Host-Pathogen Quorum Sensing and Facilitates Selection of Bioactive Metabolites in Mesenchymal Stromal Cells andACS applied materials & interfaces · 2024Article
- Regulating the bioactivity of non-glycosylated recombinant human bone morphogenetic protein-2 to enhance bone regeneration.Bioactive materials · 2024Article
- Hybrid Micro-/Nanoprotein Platform Provides Endocrine-like and Extracellular Matrix-like Cell Delivery of Growth Factors.ACS applied materials & interfaces · 2024Article
- Recombinantly expressed rhFEB remodeled the skin defect of db/db mice.Applied microbiology and biotechnology · 2024Article
- An injectable bioactive dressing based on platelet-rich plasma and nanoclay: Sustained release of deferoxamine to accelerate chronic wound healing.Acta pharmaceutica Sinica. B · 2023Article
- An engineered periosteum for efficient delivery of rhBMP-2 and mesenchymal progenitor cells during bone regeneration.NPJ Regenerative medicine · 2023Article
- Engineered Biomimetic Fibrillar Fibronectin Matrices Regulate Cell Adhesion Initiation, Migration, and Proliferation via α5β1 Integrin and Syndecan-4 Crosstalk.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Engineered dual affinity protein fragments to bind collagen and capture growth factors.Materials today. Bio · 2023Article
- Fine-Tuning Regulation of Surface Mobility by Acrylate Copolymers and Its Effect on Cell Adhesion and Differentiation.ACS applied bio materials · 2023Article
- Material-driven fibronectin and vitronectin assembly enhances BMP-2 presentation and osteogenesis.Materials today. Bio · 2022Article
- Mimicking Bone Extracellular Matrix: From BMP-2-Derived Sequences to Osteogenic-Multifunctional Coatings.Advanced healthcare materials · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Growth factors (GFs) are powerful signaling molecules with the potential to drive regenerative strategies, including bone repair and vascularization. However, GFs are typically delivered in soluble format at supraphysiological doses because of rapid clearance and limited therapeutic impact. These high doses have serious side effects and are expensive. Although it is well established that GF interactions with extracellular matrix proteins such as fibronectin control GF presentation and activity, a translation-ready approach to unlocking GF potential has not been realized. We demonstrate a simple, robust, and controlled material-based approach to enhance the activity of GFs during tissue healing. The underlying mechanism is based on spontaneous fibrillar organization of fibronectin driven by adsorption onto the polymer poly(ethyl acrylate). Fibrillar fibronectin on this polymer, but not a globular conformation obtained on control polymers, promotes synergistic presentation of integrin-binding sites and bound bone morphogenetic protein 2 (BMP-2), which enhances mesenchymal stem cell osteogenesis in vitro and drives full regeneration of a nonhealing bone defect in vivo at low GF concentrations. This simple and translatable technology could unlock the full regenerative potential of GF therapies while improving safety and cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.